A detailed history of Soleus Capital Management, L.P. transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 785,546 shares of ENTA stock, worth $4.93 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
785,546
Previous 799,546 1.75%
Holding current value
$4.93 Million
Previous $10.4 Million 21.45%
% of portfolio
0.69%
Previous 1.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.05 - $16.54 $140,700 - $231,560
-14,000 Reduced 1.75%
785,546 $8.15 Million
Q2 2024

Aug 14, 2024

BUY
$11.43 - $17.02 $2.5 Million - $3.73 Million
219,000 Added 37.72%
799,546 $10.4 Million
Q1 2024

May 15, 2024

BUY
$10.08 - $17.46 $5.85 Million - $10.1 Million
580,546 New
580,546 $10.1 Million
Q1 2023

May 15, 2023

SELL
$38.82 - $54.59 $826,866 - $1.16 Million
-21,300 Reduced 15.46%
116,514 $4.71 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $603,396 - $795,204
14,800 Added 12.03%
137,814 $6.41 Million
Q3 2022

Nov 14, 2022

BUY
$48.29 - $71.27 $1.11 Million - $1.64 Million
23,014 Added 23.01%
123,014 $6.38 Million
Q2 2022

Aug 15, 2022

SELL
$38.13 - $76.93 $3.91 Million - $7.88 Million
-102,485 Reduced 50.61%
100,000 $4.73 Million
Q1 2022

May 16, 2022

SELL
$56.06 - $74.11 $6.49 Million - $8.58 Million
-115,790 Reduced 36.38%
202,485 $14.4 Million
Q4 2021

Feb 14, 2022

BUY
$60.19 - $97.37 $8.18 Million - $13.2 Million
135,875 Added 74.49%
318,275 $23.8 Million
Q3 2021

Nov 15, 2021

BUY
$41.02 - $58.65 $7.48 Million - $10.7 Million
182,400 New
182,400 $10.4 Million
Q4 2020

Feb 16, 2021

SELL
$41.16 - $47.47 $473,339 - $545,905
-11,500 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$46.37 - $57.58 $41,733 - $51,822
900 Added 8.49%
11,500 $577,000
Q1 2020

May 15, 2020

BUY
$40.22 - $62.0 $426,332 - $657,200
10,600 New
10,600 $545,000

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $130M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.